Veracyte Inc. (VCYT)
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving Average
Veracyte (VCYT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VCYT broke out above the 50-day moving average, suggesting a short-term bullish trend.
Is Veracyte Stock the Right Pick for Your Portfolio Now?
VCYT rides on Afirma and Decipher growth with strong earnings beat and liquidity, but macro pressures and rising competition cloud its near-term outlook.
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT
Bamco Inc. NY lowered its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 645,621 shares of the biotechnology company's stock after selling 231,579 shares during the quarter. Bamco
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises
VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.
Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings
VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.
Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Veracyte (VCYT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now
Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
